VPC
CNTA

Vestal Point Capital’s Centessa Pharmaceuticals CNTA Stock Holding History

Vestal Point Capital’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-14,888
Closed -$214K – 74
2025
Q1 		$214K Buy
+14,888
New +$244K 0.02% 63

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vestal Point Capital's CNTA Position: Q2 2025 in Review

Vestal Point Capital sold out of Centessa Pharmaceuticals (CNTA) in Q2 2025, closing a stake of 14,888 shares — an estimated $214K sold.

Vestal Point Capital first reported a position in CNTA in Q1 2025 and held it in 1 quarter. The position peaked at $214K in Q1 2025. 117 funds tracked by Wall St. Rank hold CNTA as of Q2 2025.

  • Vestal Point Capital reported no remaining Centessa Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Vestal Point Capital sold 14,888 Centessa Pharmaceuticals shares in Q2 2025, an estimated $214K.
  • Vestal Point Capital first reported a position in Centessa Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • Vestal Point Capital's Centessa Pharmaceuticals position peaked at $214K in Q1 2025.
  • 117 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2025.

Based on Vestal Point Capital's 13F filing for Q2 2025, filed 14 Aug 2025.